Do common TCN2 and MTRR variants raise homocysteine by impairing vitamin B12 delivery and recycling?

Genetic variants in TCN2 and MTRR alter the delivery and utilization of vitamin B12, acting as key genetic determinants of plasma homocysteine levels. However, their phenotypic expression is highly dependent on nutritional cofactor status.

Mechanistic pathway disruption

• Transcobalamin Transport (TCN2): The common TCN2 rs1801198 (c.776C>G, p.Pro259Arg) polymorphism decreases plasma and cellular concentrations of active transcobalamin (holotranscobalamin). This reduction impairs cellular delivery and uptake of cobalamin, creating a localized, intracellular B12 insufficiency.
• Intracellular Recycling (MTRR): The MTRR rs1801394 (c.66A>G, p.Ile22Met) variant reduces the kinetic efficiency of methionine synthase reductase. This enzyme is required to regenerate active methylcobalamin, which serves as a vital cofactor for methionine synthase during the remethylation of homocysteine to methionine.

Impact of nutritional cofactor status

• Nutrient-Gene Interactions: In individuals with adequate vitamin B12 and folate levels, the metabolic bottlenecks caused by these variants are largely compensated for, resulting in negligible effects on fasting homocysteine levels.
• Exacerbation under Suboptimal Status: When systemic folate or vitamin B12 levels are compromised or marginal, the enzymatic and transport limitations of the TCN2 (rs1801198) and MTRR (rs1801394) variants are fully exposed. In these compromised states, the impaired recycling and cellular delivery pathways prevent efficient homocysteine clearance, significantly increasing the risk and severity of elevated plasma homocysteine.

Bottom line

Common TCN2 and MTRR variants compromise cellular vitamin B12 delivery and recycling, but their capacity to elevate homocysteine is fundamentally modulated by nutritional status, primarily manifesting when folate or B12 levels are suboptimal.